Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anadys Pharmaceuticals, Inc.

http://www.anadyspharma.com/

Latest From Anadys Pharmaceuticals, Inc.

Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline

Regenerative Medicine Innovation

Abecma Or Bust: 2seventy Sells Final Research Program To Novo

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

Deals Research & Development

Finance Watch: More Than $2.5bn In New VC Funding, Capital For Pharma Manufacturing In Africa

Private Company Edition: J.P. Morgan raised more than $500m in its first venture fund and the Africa Health Security Investment Plan gained $2bn. Also, Marea launched with $190m, Iambic’s series B expanded to $150m, InduPro raised an $85m series A and Elion closed an $81m series B.

Financing Innovation

Naloxone Firms Commit To Boost Capacities In White House Opioid Overdose Epidemic Meeting

Emergent BioSolutions, Harm Reduction Therapetuics, Hikma, Teva and other drug manufacturers commit to increased supply of naloxone and nalmefene in meeting with ]White House Office of National Drug Control.

Prescription To OTC Switch Politics
See All

Company Information

UsernamePublicRestriction

Register